Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology in regulatory development. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins, and injectable dermal fillers.
企業コードEOLS
会社名Evolus Inc
上場日Feb 08, 2018
最高経営責任者「CEO」Mr. David Moatazedi
従業員数332
証券種類Ordinary Share
決算期末Feb 08
本社所在地520 Newport Center Dr Ste 1200
都市NEWPORT BEACH
証券取引所NASDAQ Global Market Consolidated
国United States of America
郵便番号92660-7022
電話番号19492844555
ウェブサイトhttps://www.evolus.com/
企業コードEOLS
上場日Feb 08, 2018
最高経営責任者「CEO」Mr. David Moatazedi
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし